Virna Schuck

959 total citations
17 papers, 591 citations indexed

About

Virna Schuck is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Virna Schuck has authored 17 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 7 papers in Molecular Medicine and 5 papers in Epidemiology. Recurrent topics in Virna Schuck's work include Antibiotics Pharmacokinetics and Efficacy (9 papers), Antibiotic Resistance in Bacteria (7 papers) and Cancer therapeutics and mechanisms (4 papers). Virna Schuck is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (9 papers), Antibiotic Resistance in Bacteria (7 papers) and Cancer therapeutics and mechanisms (4 papers). Virna Schuck collaborates with scholars based in United States, Australia and Sweden. Virna Schuck's co-authors include Wright W. Nichols, Hartmut Derendorf, Jared L. Crandon, Mary Anné Banevicius, David P. Nicolau, Seyedmojtaba Seyedmousavi, Johanna Berkhout, Johan W. Mouton, Maria J. Melchers and Sherwin K. B. Sy and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Nature Chemical Biology.

In The Last Decade

Virna Schuck

16 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Virna Schuck United States 12 311 302 170 165 65 17 591
Pauline A. Lang United Kingdom 11 281 0.9× 140 0.5× 112 0.7× 193 1.2× 71 1.1× 14 487
Stephan Beisken United States 16 411 1.3× 206 0.7× 155 0.9× 319 1.9× 14 0.2× 32 813
Zishuo Cheng United States 17 507 1.6× 197 0.7× 152 0.9× 293 1.8× 38 0.6× 29 820
Robert E. Lee Trout United States 8 222 0.7× 121 0.4× 87 0.5× 136 0.8× 113 1.7× 10 440
Gail G. Hammond United States 11 468 1.5× 198 0.7× 170 1.0× 186 1.1× 197 3.0× 13 714
Britt Jansson Sweden 14 305 1.0× 320 1.1× 192 1.1× 118 0.7× 14 0.2× 18 804
Kerri M. Smith United States 13 199 0.6× 123 0.4× 64 0.4× 214 1.3× 49 0.8× 18 488
Raymond T. Testa United States 15 453 1.5× 432 1.4× 131 0.8× 242 1.5× 137 2.1× 25 801
Rajbharan Yadav United States 16 276 0.9× 243 0.8× 118 0.7× 124 0.8× 8 0.1× 29 567
Allie Y. Chen United States 6 169 0.5× 78 0.3× 72 0.4× 156 0.9× 66 1.0× 7 401

Countries citing papers authored by Virna Schuck

Since Specialization
Citations

This map shows the geographic impact of Virna Schuck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virna Schuck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virna Schuck more than expected).

Fields of papers citing papers by Virna Schuck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virna Schuck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virna Schuck. The network helps show where Virna Schuck may publish in the future.

Co-authorship network of co-authors of Virna Schuck

This figure shows the co-authorship network connecting the top 25 collaborators of Virna Schuck. A scholar is included among the top collaborators of Virna Schuck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virna Schuck. Virna Schuck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Polasek, Thomas M., Viviana Bozón, Jonathan Novak, et al.. (2025). First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14. Clinical Pharmacology in Drug Development. 14(7). 493–504.
2.
Polasek, Thomas M. & Virna Schuck. (2023). Improving the Efficiency of Clinical Pharmacology Studies. Clinical Pharmacology in Drug Development. 12(8). 771–774. 2 indexed citations
3.
Gosselin, Nathalie, et al.. (2022). Translational Population‐Pharmacodynamic Modeling of a Novel Long‐Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia. Clinical Pharmacology & Therapeutics. 113(2). 328–338. 8 indexed citations
4.
Rayner, Craig R., Patrick F. Smith, David R. Andes, et al.. (2021). Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future. Clinical Pharmacology & Therapeutics. 109(4). 867–891. 53 indexed citations
5.
Basarab, Gregory S., P. Doig, Charles J. Eyermann, et al.. (2020). Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase. Journal of Medicinal Chemistry. 63(20). 11882–11901. 15 indexed citations
6.
Naderer, Odin, et al.. (2018). 1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects. Open Forum Infectious Diseases. 5(suppl_1). S438–S439. 2 indexed citations
7.
Sy, Sherwin K. B., Luning Zhuang, Huiming Xia, et al.. (2018). A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 73(5). 1295–1304. 23 indexed citations
8.
Sy, Sherwin K. B., Luning Zhuang, Philipp Kircher, et al.. (2016). Potentiation of ceftazidime by avibactam against β-lactam-resistantPseudomonas aeruginosain anin vitroinfection model. Journal of Antimicrobial Chemotherapy. 72(4). dkw535–dkw535. 18 indexed citations
9.
Sy, Sherwin K. B., Luning Zhuang, Christian Frank, et al.. (2016). In vitropharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. Journal of Antimicrobial Chemotherapy. 71(7). 1866–1880. 34 indexed citations
10.
Walkup, Grant K., Philip L. Ross, Fereidoon Daryaee, et al.. (2015). Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nature Chemical Biology. 11(6). 416–423. 116 indexed citations
11.
Berkhout, Johanna, Maria J. Melchers, Seyedmojtaba Seyedmousavi, et al.. (2015). Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Antimicrobial Agents and Chemotherapy. 60(1). 368–375. 90 indexed citations
12.
Basarab, Gregory S., Patrick Brassil, P. Doig, et al.. (2014). Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization. Journal of Medicinal Chemistry. 57(21). 9078–9095. 44 indexed citations
13.
Visser, Sandra A. G., Rhys D.O. Jones, Virna Schuck, et al.. (2013). Model-based drug discovery: implementation and impact. Drug Discovery Today. 18(15-16). 764–775. 46 indexed citations
14.
Crandon, Jared L., et al.. (2012). Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 56(12). 6137–6146. 104 indexed citations
15.
Schuck, Virna, et al.. (2004). In vitro microdialysis sampling of docetaxel. Journal of Pharmaceutical and Biomedical Analysis. 36(4). 807–813. 17 indexed citations
16.
Schuck, Virna, et al.. (2002). Compartmental analysis of ranitidine doubled peak plasma profile after oral administration to healthy volunteers. Revista Brasileira de Ciência do Solo. 38(2). 6 indexed citations
17.
Schuck, Virna, et al.. (2001). Avaliacao da atividade antimicrobiana de Cymbopogon citratus. 37(1). 45–49. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pauline A. Lang Breakdown of academic impact, for papers by Stephan Beisken Breakdown of academic impact, for papers by Zishuo Cheng Breakdown of academic impact, for papers by Robert E. Lee Trout Breakdown of academic impact, for papers by Gail G. Hammond Breakdown of academic impact, for papers by Britt Jansson Breakdown of academic impact, for papers by Kerri M. Smith Breakdown of academic impact, for papers by Raymond T. Testa Breakdown of academic impact, for papers by Rajbharan Yadav Breakdown of academic impact, for papers by Allie Y. Chen
Rankless by CCL
2026